Lineage Cell Therapeutics (LCTX) Share-based Compensation (2010 - 2026)

Lineage Cell Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $40000.0 for Q1 2026.

• In Q1 2026, Share-based Compensation rose 166.67% year-over-year to $40000.0; the TTM figure through Mar 2026 stood at -$1.2 million (down 129.55% YoY), while the FY2025 annual figure was $6.2 million, down 24.39% from the prior year.
• Share-based Compensation for Q1 2026 stood at $40000.0, up from -$3.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $1.3 million in Q3 2024, with the low at -$3.6 million in Q4 2025.
• The 5-year median for Share-based Compensation is $1.2 million (2024), against an average of $756352.9.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation slumped 376.65% in 2025, then jumped 166.67% in 2026.
• Lineage Cell Therapeutics' Share-based Compensation stood at $959000.0 in 2022, then increased by 10.53% to $1.1 million in 2023, then advanced by 24.06% to $1.3 million in 2024, then plunged by 376.65% to -$3.6 million in 2025, then soared by 101.1% to $40000.0 in 2026.
• Business Quant data shows LCTX's Share-based Compensation at $40000.0 in Q1 2026, -$3.6 million in Q4 2025, and $1.2 million in Q3 2025.